ReviewAnnals of oncology : official journal of the European Society for Medical Oncology2012
The sequential use of endocrine treatment for advanced breast cancer: where are we?
Review in Annals of oncology : official journal of the European Society for Medical Oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- SEOM clinical guidelines for the management of metastatic breast cancer 2013.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2013Guideline
- Trial
- Article
- Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer.bioRxiv : the preprint server for biology · 2025Article
- Review
- A BIRC5Cancer informatics · 2022Article
- Survival analysis of bevacizumab plus taxane treatment in luminal metastatic breast cancer.Future science OA · 2021Article
- Endocrine Therapy-related Endocrinopathies-Biology, Prevalence and Implications for the Management of Breast Cancer.Oncology & hematology review · 2020Article
- Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study.Scientific reports · 2019Article
- IL-1 induces p62/SQSTM1 and autophagy in ERαJournal of cellular biochemistry · 2019Article
- SETNPJ breast cancer · 2019Article
- Review
- Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.The oncologist · 2017Article
- Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer.Breast cancer (Dove Medical Press) · 2016Review
- Optimal management of hormone receptor positive metastatic breast cancer in 2016.Therapeutic advances in medical oncology · 2015Review
- Treating Elderly Patients With Hormone Receptor-Positive Advanced Breast Cancer.Clinical Medicine Insights. Oncology · 2015Review
- Insulin-like growth factor and epidermal growth factor signaling in breast cancer cell growth: focus on endocrine resistant disease.Analytical cellular pathology (Amsterdam) · 2015Review
- Mathematical models of the transitions between endocrine therapy responsive and resistant states in breast cancer.Journal of the Royal Society, Interface · 2014Article
- Considerations for payers in managing hormone receptor-positive advanced breast cancer.ClinicoEconomics and outcomes research : CEOR · 2014Review
- Paradoxal metabolic flare detected by 18F-fluorodeoxyglucose positron emission tomography in a patient with metastatic breast cancer treated with aromatase inhibitor and biphosphonate.Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundHormone receptor-positive advanced breast cancer is an increasing health burden. Although endocrine therapies are recognised as the most beneficial treatments for patients with hormone receptor-positive advanced breast cancer, the optimal sequence of these agents is currently undetermined.
methodsWe reviewed the available data on randomised controlled trials (RCTs) of endocrine therapies in this treatment setting with particular focus on RCTs reported over the last 15 years that were designed based on power calculations on primary end points.
resultsIn this paper, data are reviewed in postmenopausal patients for the use of tamoxifen, aromatase inhibitors and fulvestrant. We also consider the available data on endocrine crossover studies and endocrine therapy in combination with chemotherapy or growth factor therapies. Treatment options for premenopausal patients and those with estrogen receptor-/human epidermal growth factor receptor 2-positive tumours are also evaluated.
conclusionWe present the level of evidence available for each endocrine agent based on its efficacy in advanced breast cancer and a diagram of possible treatment pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.